Skip to main content

Advertisement

Fig. 1 | BMC Pulmonary Medicine

Fig. 1

From: Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis

Fig. 1

Decline of FVC per month during the administration period of pirfenidone and after switching to nintedanib. Only ten patients could perform lung function tests at 6 months after switching to nintedanib. However, in seven of ten patients (70%), nintedanib suppressed FVC decline compared with that during the administration period of pirfenidone

Back to article page